Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1998 1
2004 3
2005 3
2008 1
2017 1
2018 2
2019 3
2020 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for K. S. harikumar
Your search for K. S. Arikumar retrieved no results
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Drysdale SB, et al. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189. N Engl J Med. 2023. PMID: 38157500 Clinical Trial.
Randomized Trial of Platelet-Transfusion Thresholds in Neonates.
Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D'Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T; PlaNeT2 MATISSE Collaborators. Curley A, et al. N Engl J Med. 2019 Jan 17;380(3):242-251. doi: 10.1056/NEJMoa1807320. Epub 2018 Nov 2. N Engl J Med. 2019. PMID: 30387697 Clinical Trial.
Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen.
Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E, Johnson S, Kelsall W, Pepperell J, Roberts T, Sinha S, Stanbury K, Wyllie J, Hardy P, Juszczak E; Baby-OSCAR Collaborative Group. Gupta S, et al. N Engl J Med. 2024 Jan 25;390(4):314-325. doi: 10.1056/NEJMoa2305582. N Engl J Med. 2024. PMID: 38265644 Free PMC article. Clinical Trial.
Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus.
Mohammed S, Vineetha NS, James S, Aparna JS, Lankadasari MB, Allegood JC, Li QZ, Spiegel S, Harikumar KB. Mohammed S, et al. FASEB J. 2019 Jun;33(6):7061-7071. doi: 10.1096/fj.201802535R. Epub 2019 Mar 6. FASEB J. 2019. PMID: 30840833 Free PMC article.
Yet, because its deletion had no effect on the clinical lupus parameters in this preclinical model, inhibitors of SphK2 might not be useful for treatment of this devastating disease.-Mohammed, S., Vineetha, N. S., James, S., Aparna, J. S., Lankadasari, …
Yet, because its deletion had no effect on the clinical lupus parameters in this preclinical model, inhibitors of SphK2 might not be useful …
A Review on the Anesthetic Management of Patients with Neuromuscular Diseases.
Radkowski P, Suren L, Podhorodecka K, Harikumar S, Jamrozik N. Radkowski P, et al. Anesth Pain Med. 2023 Jan 25;13(1):e132088. doi: 10.5812/aapm-132088. eCollection 2023 Feb. Anesth Pain Med. 2023. PMID: 37409004 Free PMC article. Review.
CONCLUSIONS: Problems of anesthesia in patients with NMDs arise from the nature of the condition itself and the interaction of anesthetics and muscle relaxants with anticholinesterase drugs used in therapy. Each patient's individual risk should be assessed before anesthesi …
CONCLUSIONS: Problems of anesthesia in patients with NMDs arise from the nature of the condition itself and the interaction of anesthetics a …
Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
Harikumar KG, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 May 13;280(19):18631-5. doi: 10.1074/jbc.M410834200. Epub 2005 Mar 9. J Biol Chem. 2005. PMID: 15757907 Free article.
We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., …
We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and with …
Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 Jan 21;280(3):2176-85. doi: 10.1074/jbc.M410385200. Epub 2004 Nov 10. J Biol Chem. 2005. PMID: 15537636 Free article.
Receptor conformation was probed with a fluorescent full agonist ligand, Alexa 488-conjugated Gly-[Nle(28,31)]CCK-(26-33), shown previously to decrease in anisotropy and lifetime when occupying a receptor in the active conformation (Harikumar, K. G., Pinon, D. L., W …
Receptor conformation was probed with a fluorescent full agonist ligand, Alexa 488-conjugated Gly-[Nle(28,31)]CCK-(26-33), shown previously …
Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ. Harikumar KG, et al. J Biol Chem. 2005 Jan 14;280(2):1044-50. doi: 10.1074/jbc.M409480200. Epub 2004 Nov 1. J Biol Chem. 2005. PMID: 15520004 Free article.
We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa488-Gly-[(Nle(28,31))CCK-26-33]; CCK-8 probe) bound to the type A CCK receptor (Harikumar, K. G., Pinon, D. L., Wessels, W. S., Prendergast, F. …
We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa488-Gly-[(Nle(28,31))CCK- …
Rational development of a high-affinity secretin receptor antagonist.
Dong M, Harikumar KG, Raval SR, Milburn JE, Clark C, Alcala-Torano R, Mobarec JC, Reynolds CA, Ghirlanda G, Christopoulos A, Wootten D, Sexton PM, Miller LJ. Dong M, et al. Biochem Pharmacol. 2020 Jul;177:113929. doi: 10.1016/j.bcp.2020.113929. Epub 2020 Mar 23. Biochem Pharmacol. 2020. PMID: 32217097 Free PMC article.
Alanine-replacement mutagenesis of these residues markedly affected ligand binding and biological activity. The optimal antagonist ligand, (Y(10),c[E(16),K(20)],I(17),Cha(22),R(25))sec(6-27), exhibited high binding affinity (4 nM), similar to natural secretin, and exhibite …
Alanine-replacement mutagenesis of these residues markedly affected ligand binding and biological activity. The optimal antagonist ligand, ( …
16 results